Hematology

A topic in the Science corpus, drawn from 1,866 papers.

Trusted voices in Hematology

Ordered by the trust Hematology's own network concentrates on each researcher, most first.

  1. Irving L. Weissman — trusted by 34 researchers here
  2. S. Coughlin — trusted by 20 researchers here
  3. T. Ganz — trusted by 19 researchers here
  4. Zena Werb — trusted by 23 researchers here
  5. I. Weinstein — trusted by 15 researchers here
  6. S. Badylak — trusted by 14 researchers here
  7. C. A. Dinarello — trusted by 8 researchers here
  8. C. Sawyers — trusted by 11 researchers here
  9. T. Kishimoto — trusted by 11 researchers here
  10. J. Heit — trusted by 6 researchers here
  11. Stuart H. Orkin — trusted by 10 researchers here
  12. Eric P. Skaar — trusted by 8 researchers here

Most-cited papers in Hematology

Ordered by the recorded citation count from the source corpus; a citation is not an endorsement.

  1. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (2012, Annals of the Rheumatic Diseases) — 14,291 citations
  2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016, Blood) — 8,916 citations
  3. COVID-19: consider cytokine storm syndromes and immunosuppression (2020, The Lancet) — 8,587 citations
  4. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury (2007, Critical Care) — 6,821 citations
  5. Chronic kidney disease (2012, The Lancet) — 6,497 citations
  6. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) (2006, Journal of Thrombosis and Haemostasis) — 6,323 citations
  7. Maternal and child undernutrition: global and regional exposures and health consequences. (2008, The Lancet) — 6,301 citations
  8. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death (2015, Nature) — 5,789 citations
  9. Efficacy and safety of recombinant human activated protein C for severe sepsis. (2001, New England Journal of Medicine) — 5,337 citations
  10. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001, New England Journal of Medicine) — 5,221 citations
  11. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, Blood) — 5,186 citations
  12. HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis (2007, Pediatric Blood & Cancer) — 5,036 citations
  13. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment (2010, Cell) — 4,956 citations
  14. Complement Factor H Polymorphism in Age-Related Macular Degeneration (2005, Science) — 4,849 citations
  15. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. (2009, Blood) — 4,767 citations
  16. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia (2013, New England Journal of Medicine) — 4,584 citations
  17. IL-6 in inflammation, immunity, and disease. (2014, Cold Spring Harbor Perspectives in Biology) — 4,456 citations
  18. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization (2004, Science) — 4,434 citations
  19. The resurgence of platinum-based cancer chemotherapy (2007, Nature Reviews. Cancer) — 4,374 citations
  20. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002, New England Journal of Medicine) — 4,306 citations
  21. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014, The Lancet Oncology) — 4,253 citations
  22. Age-related clonal hematopoiesis associated with adverse outcomes. (2014, New England Journal of Medicine) — 4,169 citations
  23. How matrix metalloproteinases regulate cell behavior. (2001, Annual Review of Cell and Developmental Biology) — 4,072 citations
  24. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report (2005, Biology of Blood and Marrow Transplantation) — 4,059 citations
  25. Selective inhibition of BET bromodomains (2010, Nature) — 4,002 citations
  26. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. (2005, The Lancet) — 3,720 citations
  27. A gain-of-function mutation of JAK2 in myeloproliferative disorders. (2005, New England Journal of Medicine) — 3,651 citations
  28. Osteoblastic cells regulate the haematopoietic stem cell niche (2003, Nature) — 3,638 citations
  29. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003, New England Journal of Medicine) — 3,629 citations
  30. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (2010, New England Journal of Medicine) — 3,615 citations
  31. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005, PLoS Medicine) — 3,566 citations
  32. Genomic Classification and Prognosis in Acute Myeloid Leukemia (2016, New England Journal of Medicine) — 3,531 citations
  33. Cellular processing of platinum anticancer drugs (2005, Nature reviews. Drug discovery) — 3,529 citations
  34. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022, Leukemia) — 3,492 citations
  35. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006, New England Journal of Medicine) — 3,470 citations
  36. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants (2002, Science) — 3,456 citations
  37. Artemisinin Resistance in Plasmodium falciparum Malaria (2009, New England Journal of Medicine) — 3,357 citations
  38. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera (2005, Nature) — 3,352 citations
  39. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (2011, New England Journal of Medicine) — 3,340 citations
  40. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche (2010, Nature) — 3,309 citations
  41. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling (2015, Nature) — 3,299 citations
  42. Guidelines for the Early Management of Adults With Ischemic Stroke (2007) — 3,294 citations
  43. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (2001, Science) — 3,268 citations
  44. Genomic aberrations and survival in chronic lymphocytic leukemia. (2000, New England Journal of Medicine) — 3,254 citations
  45. The impact of the use of different types of gloves and bare hands for preparation of clean surgical instruments (2016, Revista Latino-Americana de Enfermagem) — 3,190 citations
  46. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005, Cancer Cell) — 3,130 citations
  47. Identification of the haematopoietic stem cell niche and control of the niche size (2003, Nature) — 3,115 citations
  48. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2000, New England Journal of Medicine) — 3,098 citations
  49. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence (2014, New England Journal of Medicine) — 3,098 citations
  50. Revised international prognostic scoring system for myelodysplastic syndromes. (2012, Blood) — 2,977 citations

Most active researchers

By papers in this topic: a volume measure, not trust.